Pulmonary Fibrosis is a progressive and debilitating lung condition characterized by the scarring or fibrosis of lung tissue. In this disorder, the normal lung architecture is replaced by excessive fibrous connective tissue, impairing the lung's ability to function properly. The scarring results in stiff and less elastic lungs, making it challenging for them to expand and contract during breathing. Idiopathic pulmonary fibrosis (IPF) is the most common form of the disease, where the exact cause is unknown. Other types may be linked to environmental exposures, autoimmune diseases, or medications. Symptoms of pulmonary fibrosis include persistent cough, shortness of breath, fatigue, and respiratory failure over time. Diagnosis typically involves imaging studies, lung function tests, and sometimes a lung biopsy. Unfortunately, there is currently no cure for pulmonary fibrosis, and treatment options primarily focus on managing symptoms and slowing disease progression. Medications, oxygen therapy, and lung transplantation may be considered in advanced cases. Ongoing research seeks to better understand the underlying mechanisms and develop targeted therapies to improve the prognosis and quality of life for individuals affected by pulmonary fibrosis. Early detection and a multidisciplinary approach remain crucial in managing this challenging lung condition.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Will be updated soon...
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : Will be updated soon...
Nagy Habib, Imperial College London, United Kingdom
Title : Will be updated soon...
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : Developing iPSC-derived 3D Outer Blood-Retinal Barrier Disease Models of Choroideremia for Gene Therapy Evaluation
Aradhana Kasimsetty, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), United States